Background: The receptor for advanced glycation end-products (RAGE) is a multiligand transmembrane receptor that is overexpressed in various pathological conditions including cancers. However, the expression pattern of RAGE in breast cancer tumors is still not completely clear. Methods: In this study, we investigated the expression levels of RAGE in 25 fresh-frozen breast cancer samples and corresponding noncancerous tissue samples collected from breast cancer patients, by real-time polymerase chain reaction (PCR). Additionally, we performed immunohistochemistry on breast cancer specimens. Results: The results indicate a high expression of the RAGE-encoding gene in the cancerous tissues. RAGE expression at the mRNA and protein levels was statistically significantly up-regulated in advanced-stage and triple-negative breast tumors and node-positive tissues compared with other tissues (p < 0.001). A significant association between RAGE expression and tumor size was observed (p = 0.029). Conclusions: Overexpression of RAGE in advanced-stage tumors may be a useful biomarker for diagnosis and the prediction of breast cancer progression.

1.
American Cancer Society: Global Cancer Facts &amp; Figures, ed 3. Atlanta, American Cancer Society, 2015.
2.
Li J, Shao Z: Mammography screening in less developed countries. Springerplus 2015;4:615.
[PubMed]
3.
Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005.
[PubMed]
4.
Checka CM, Chun JE, Schnabel FR, Lee J, Toth H: The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol 2012;198:W292-W295.
[PubMed]
5.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312.
[PubMed]
6.
Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005;83:876-886.
[PubMed]
7.
Han SH, Kim YH, Mook-Jung I: RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011;31:91-97.
[PubMed]
8.
Bierhaus A, Stern DM, Nawroth PP: RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006;7:985-991.
[PubMed]
9.
Moridi H, Karimi J, Sheikh N, Goodarzi MT, Saidijam M, Yadegarazari R, Khazaei M, Khodadadi I, Tavilani H, Piri H, Asadi S, Zarei S, Rezaei A: Resveratrol-dependent down-regulation of receptor for advanced glycation end-products and oxidative stress in kidney of rats with diabetes. Int J Endocrinol Metab 2015;13: e23542.
[PubMed]
10.
Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-955.
[PubMed]
11.
Dougan M, Dranoff G: Inciting inflammation: the RAGE about tumor promotion. J Exp Med 2008;205:267-270.
[PubMed]
12.
Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, Sasaki N, Yamagishi S, Takeuchi M, Shimizu H: Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004;122:461-467.
[PubMed]
13.
Kuniyasu H, Chihara Y, Takahashi T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003;10:445-448.
[PubMed]
14.
Qian F, Sun BL, Zhang WY, Ke J, Zhu J: Gly82Ser polymorphism of the receptor for advanced glycation end-product (RAGE) potential high risk in patients with colorectal cancer. Tumour Biol 2014;35:3171-3175.
[PubMed]
15.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
[PubMed]
16.
Zhu X, Jin L, Zou S, Shen Q, Jiang W, Lin W, Zhu X: Immunohistochemical expression of RAGE and its ligand (S100A9) in cervical lesions. Cell Biochem Biophys 2013;66:843-850.
[PubMed]
17.
Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
[PubMed]
18.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
[PubMed]
19.
Polyak K: Heterogeneity in breast cancer. J Clin Invest 2011;121:3786-3788.
[PubMed]
20.
Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D: Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279.
[PubMed]
21.
Elsamany S, Abdullah S: Triple-negative breast cancer: future prospects in diagnosis and management. Med Oncol 2014;31:834.
[PubMed]
22.
Yan SF, Ramasamy R, Schmidt AM: Receptor for AGE (RAGE) and its ligands - cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) 2009;87:235-247.
[PubMed]
23.
Yamagishi S, Matsui T, Fukami K: Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk. Rejuvenation Res 2015;18:48-56.
[PubMed]
24.
Bao JM, He MY, Liu YW, Lu YJ, Hong YQ, Luo HH, Ren ZL, Zhao SC, Jiang Y: AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. Am J Cancer Res 2015;5:1741-1750.
[PubMed]
25.
Wang D, Li T, Ye G, Shen Z, Hu Y, Mou T, Yu J, Li S, Liu H, Li G: Overexpression of the receptor for advanced glycation endproducts (RAGE) is associated with poor prognosis in gastric cancer. PLoS One 2015;10:e0122697.
[PubMed]
26.
Sasahira T, Akama Y, Fujii K, Kuniyasu H: Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 2005;446:411-415.
[PubMed]
27.
Zhao CB, Bao JM, Lu YJ, Zhao T, Zhou XH, Zheng DY, Zhao SC: Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res 2014;4:369-377.
[PubMed]
28.
Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M, Zhao H, Padilla L, Zhang X, Shilo K, Ostrowski M, Shapiro C, Carson WE 3rd, Ganju RK: RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res 2015;75:974-985.
[PubMed]
29.
Kiryushko D, Novitskaya V, Soroka V, Klingelhofer J, Lukanidin E, Berezin V, Bock E: Molecular mechanisms of Ca(2+) signaling in neurons induced by the S100A4 protein. Mol Cell Biol 2006;26:3625-3638.
[PubMed]
30.
Wu JT, Kral JG: The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005;123:158-169.
[PubMed]
31.
Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, Bierhaus A, Lotze MT, Zeh HJ: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010;17:666-676.
[PubMed]
32.
Michaelson JS, Silverstein M, Sgroi D, Cheongsiatmoy JA, Taghian A, Powell S, Hughes K, Comegno A, Tanabe KK, Smith B: The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003;98:2133-2143.
[PubMed]
33.
Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, Nogueira L, Reuter VE, Russo P: Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol 2009;181:2033-2036.
[PubMed]
34.
Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R, Kebebew E, Duh QY, Clark OH: Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid. World J Surg 2008;32:702-707.
[PubMed]
35.
Arumugam T, Ramachandran V, Logsdon CD: Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98:1806-1818.
[PubMed]
36.
Schutz F, Domschke C, Schneeweiss A: Targeted therapy of HER2-negative breast cancer. Oncol Res Treat 2016;39:118-121.
[PubMed]
37.
Radia AM, Yaser AM, Ma X, Zhang J, Yang C, Dong Q, Rong P, Ye B, Liu S, Wang W: Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. Int J Mol Sci 2013;14:7959-7978.
[PubMed]
You do not currently have access to this content.